zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Transitions to Orsini as the Specialty Pharmacy Provider for OLPRUVA® (sodium phenylbutyrate), a Treatment for Certain Urea Cycle Disorders
June 18, 2024 07:30 ET | Zevra Therapeutics
CELEBRATION, Fla. and ELK GROVE VILLAGE, Ill., June 18, 2024 (GLOBE NEWSWIRE) -- Orsini Specialty Pharmacy (Orsini), and Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra) today announced that Orsini...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Announces Positive Final Results from Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia at SLEEP 2024 Annual Meeting
June 03, 2024 11:00 ET | Zevra Therapeutics
KP1077 was well tolerated and showed meaningful clinical improvements in patient-reported assessments of daytime sleepiness, sleep inertia, and brain fog Additional data presented on...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics to Participate at Upcoming Investor Events
May 09, 2024 07:30 ET | Zevra Therapeutics
CELEBRATION, Fla., May 09, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane,...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
May 08, 2024 07:00 ET | Zevra Therapeutics
Full commercial launch of OLPRUVA at the end of January 2024, with market access growing to ~75% of covered lives as of May 1, 2024 Arimoclomol NDA review underway with PDUFA date of September 21,...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics to Report First Quarter 2024 Results on May 8, 2024
May 01, 2024 07:30 ET | Zevra Therapeutics
CELEBRATION, Fla., May 01, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it will host a...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics’ President and Chief Executive Officer Issues Letter to Stockholders Highlighting Recent Key Accomplishments and Outlook for 2024
April 29, 2024 07:30 ET | Zevra Therapeutics
CELEBRATION, Fla., April 29, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that Neil F. McFarlane,...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Presents New Data on the Long-Term Safety and Efficacy of Arimoclomol as a Treatment for Niemann-Pick Disease Type C at the SIMD 45th Annual Meeting
April 15, 2024 17:01 ET | Zevra Therapeutics
The oral presentation highlighted data from Zevra’s Expanded Access Program demonstrating a consistent safety profile CELEBRATION, Fla., April 15, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics,...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Refinances Existing Debt with up to $100M in Committed Capital under New Credit Facility
April 10, 2024 07:30 ET | Zevra Therapeutics
CELEBRATION, Fla., April 10, 2024 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a rare disease therapeutics company, today announced that it has entered into...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Updates
March 28, 2024 16:32 ET | Zevra Therapeutics
Launch of OLPRUVA® underway Topline results from KP1077 phase 2 study demonstrate clinically meaningful benefits for key IH symptoms Q4 2023 net revenue of $13.2M, and FY 2023 net revenue of $27.5M ...
zevra_inline_fullcolor_rgb_12in@300ppi (1).png
Zevra Therapeutics Announces Top-Line Data from the Phase 2 Clinical Trial of KP1077 for Idiopathic Hypersomnia
March 26, 2024 16:30 ET | Zevra Therapeutics
KP1077 demonstrates clinically meaningful benefits for key IH symptoms Top-line data provide key information for the design of a Phase 3 study CELEBRATION, Fla., March 26, 2024 (GLOBE NEWSWIRE) --...